YD Bio Reports 17% Revenue Growth to $596.8M, Net Loss Widens to $8.3M
YD Bio completed its merger with Breeze Holdings in August 2025 and secured $13.2M in PIPE financing, ending 2025 with $6.0M in cash. Full-year net revenue rose 17% to $596.8M driven by pharmaceutical sales, while net loss widened to $8.31M as operating expenses jumped 226%.
1. Business Combination and PIPE Financing
YD Bio completed its merger with Breeze Holdings Acquisition Corp. in August 2025 and raised $13.2 million through a private investment in public equity. These transactions bolstered the balance sheet, leaving the company with approximately $6.0 million in cash and cash equivalents at year-end.
2. Financial Performance
Full-year net revenue increased 17% to $596.8 million driven by higher pharmaceutical sales volumes and new product launches. Operating expenses surged 236% to $5.44 million, contributing to a net loss of $8.31 million for the year.
3. R&D and Clinical Pipeline
The company boosted research and development spending by $1.1 million to secure licensed patents and support infrastructure for its diagnostics and therapeutics platforms. It filed Drug Master Files with the FDA for its limbal stem cell and exosome products and plans IND submissions for Dry Eye Disease and Age-Related Macular Degeneration in 2026.
4. Strategic Outlook and M&A
YD Bio is advancing its OkaiDx™ Pancreatic Cancer Early Detection Program toward an FDA Q-Submission for Breakthrough Device eligibility and scaling its EG Telehealth Platform launched in March 2026. The planned merger with EG BioMed aims to integrate AI-driven methylation analysis into its oncology pipeline.